Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2026
A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)Yasuyuki Kawamoto, Kentaro Sawada, Kazuaki Harada, et al.
Cancer Science|April 16, 2015
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with PalonosetronYoshito Komatsu, Kenji Okita, Satoshi Yuki, et al.
Pancreas|June 13, 2022
Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived SamplesShintaro Nakano, Yasuyuki Kawamoto, Yoshito Komatsu, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2017
Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitorsYoshihiro Usui, Fumiaki Uehara, Shinsuke Hiki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Comprehensive Genomic and Transcriptomic Characterization of MTAP Loss Across Advanced Solid TumorsKyosuke Seguchi, Takao Fujisawa, Sadakatsu Ikeda, et al.
Future Oncology (London, England)|February 17, 2015
Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPPYoshimitsu Kobayashi, Yoshito Komatsu, Satoshi Yuki, et al.
British Journal of Cancer|June 4, 2024
Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancerYuichiro Tsukada, Hideaki Bando, Koji Inamori, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 16, 2022
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancerKen Ito, Satoshi Yuki, Hiroshi Nakatsumi, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2013
2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitorsKenji Fukunaga, Fumiaki Uehara, Keiichi Aritomo, et al.
Biomedical Reports|October 1, 2019
Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencingSatoshi Fujii, Takayuki Yoshino, Kentaro Yamazaki, et al.
Pageof 12